Skip to main content

Videos

Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma

Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

September 23, 2022

Interview with the Innovators

Broadening the Variety of Candidate Therapies for R/R Follicular Lymphoma Allows Optimal Personalized Rx Choice, While Patient-Directed Education Helps Attain Greatest Clinical Benefit

Broadening the Variety of Candidate Therapies for R/R Follicular Lymphoma Allows Optimal Personalized Rx Choice, While Patient-Directed Education Helps Attain Greatest Clinical Benefit

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

September 19, 2022

Interview with the Innovators

$Criteria Used to Guide Treatment Decisions and Choice of Therapeutic Agents in Patients with Relapsed or Refractory Follicular Lymphoma$

Criteria Used to Guide Treatment Decisions and Choice of Therapeutic Agents in Patients with Relapsed or Refractory Follicular Lymphoma

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

September 12, 2022

Interview with the Innovators

Specific Dysregulation of B-Cell Signaling in Follicular Lymphoma and Its Role in the Initiation and Progression of This Malignancy

Specific Dysregulation of B-Cell Signaling in Follicular Lymphoma and Its Role in the Initiation and Progression of This Malignancy

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

September 6, 2022

Interview with the Innovators

Spectrum of Symptoms in Patients Newly Diagnosed with Follicular Lymphoma and the Role of Optimal Coordination of Care at Initial Presentation

Spectrum of Symptoms in Patients Newly Diagnosed with Follicular Lymphoma and the Role of Optimal Coordination of Care at Initial Presentation

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

August 31, 2022

Interview with the Innovators

Epidemiology and expected survivorship in follicular lymphoma and lack of reliable long-term outcome predictors at disease presentation

Epidemiology and expected survivorship in follicular lymphoma and lack of reliable long-term outcome predictors at disease presentation

FEATURING:

Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

August 23, 2022

Interview with the Innovators

Underserved Patients with HER2-Positive mBC

Underserved Patients with HER2-Positive mBC

FEATURING:

Neil M. Iyengar, MD

July 11, 2022

Rapid Reactions

Treatment Landscape and Clinical Management of HER2-Positive mBC

Treatment Landscape and Clinical Management of HER2-Positive mBC

FEATURING:

Neil M. Iyengar, MD

July 5, 2022

Rapid Reactions

HER2-Positive mBC Trials in Progress

HER2-Positive mBC Trials in Progress

FEATURING:

Neil M. Iyengar, MD

June 27, 2022

Rapid Reactions

Page 6 of 20